| 12/03/2021 |
Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2022(IFRS) |
| 11/15/2021 |
FY2022/3 H1, Presentation (Apr.1 to Sep.30 2021) |
| 11/15/2021 |
FY2022/3 H1, Supplementary Material(Apr.1 to Sep.30 2021) |
| 09/06/2021 |
Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2022(IFRS) |
| 08/10/2021 |
Year Ending March 31, 2022 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2021) |
| 06/17/2021 |
License & Supply Agreement with Laboratorio Elea Phenix S.A. on Infliximab Biosimilar in Argentine market |
| 06/14/2021 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 (IFRS) |
| 05/29/2021 |
Notice of the 57th Ordinary General Meeting of Shareholders |
| 05/18/2021 |
F2020, ended March 2021 |
| 05/14/2021 |
Year Ended March 31, 2020 Results Settlement of Accounts Supplementary Material (Apr.1 2020 to Mar.31 2021) |
| 04/22/2021 |
Partial Delay in Supply of Products Manufactured by the Toyama Plant 1 |
| 04/06/2021 |
Notification of Resumed Operations for Manufacturing and Distribution of Pharmaceutical Products by Nichi-lko and Manufacturing of Pharmaceutical Products by the Toyama Plant 1 |
| 03/12/2021 |
Consolidated Financial Result for the 3rd Quarter of the Fiscal Year Ending March,2021(IFRS) |
| 03/03/2021 |
Administrative Disposition to our Company |
| 02/10/2021 |
FY2021/3 Q3, Supplementary Material(Apr.1 to Dec.31 2020) |
